Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 79 results found since Jan 2013.
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
ESC: Adverse Outcomes Increased With Suboptimal Adherence to Aspirin After MI
MONDAY, Aug. 28, 2023 -- Suboptimal adherence to aspirin after myocardial infarction (MI) is associated with an increased risk for recurrent MI, ischemic stroke, or death, according to a study presented at the European Society of Cardiology...
Source: Drugs.com - Pharma News - August 28, 2023 Category: Pharmaceuticals Source Type: news
P2Y ₁₂ Inhibitor Monotherapy Better Than Aspirin in Coronary Artery Disease
MONDAY, July 10, 2023 -- For patients with coronary artery disease (CAD), P2Y12 inhibitor monotherapy is associated with a lower risk for cardiovascular death, myocardial infarction, and stroke compared with aspirin monotherapy, according to a study...
Source: Drugs.com - Pharma News - July 10, 2023 Category: Pharmaceuticals Source Type: news
Women With Migraine Have Higher Risk for Heart Attack, Hemorrhagic Stroke
TUESDAY, June 13, 2023 -- The risk for ischemic stroke in individuals with migraine is similar for men and women, while the risk for myocardial infarction (MI) and hemorrhagic stroke is only higher in women with migraine, according to a study...
Source: Drugs.com - Pharma News - June 13, 2023 Category: Pharmaceuticals Source Type: news
Cancer Patients Who Continue Smoking After Diagnosis at Risk of CVD Events
FRIDAY, June 2, 2023 -- Cancer patients who continue smoking after their diagnosis have an increased risk for heart attack, stroke, or death due to cardiovascular disease (CVD) compared with nonsmokers, according to a study published online June 1...
Source: Drugs.com - Pharma News - June 2, 2023 Category: Pharmaceuticals Source Type: news
CVD Events Increased for Cancer Patients Who Continue Smoking After Diagnosis
FRIDAY, June 2, 2023 -- Cancer patients who continue smoking after their diagnosis have an increased risk for heart attack, stroke, or death due to cardiovascular disease (CVD) compared with nonsmokers, according to a study published online June 1...
Source: Drugs.com - Pharma News - June 2, 2023 Category: Pharmaceuticals Source Type: news
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Risk for MI, Ischemic Stroke Increased for Younger Adults With Mental Disorders
TUESDAY, May 9, 2023 -- Younger adults with mental disorders have an increased risk for myocardial infarction (MI) and ischemic stroke (IS), according to a study published online April 28 in the European Journal of Preventive Cardiology.
Chan Soon...
Source: Drugs.com - Pharma News - May 9, 2023 Category: Pharmaceuticals Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Cell Therapy Prevents Risk Of Heart Attack or Stroke: Study
A recent study searches for a permanent solution to repair the heart via stem cell therapy.
Source: Forbes.com Healthcare News - March 24, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
AMI, Stroke Risk Elevated for Women With Preeclampsia Within 20 Years
FRIDAY, Feb. 3, 2023 -- Women with a history of preeclampsia have a significantly increased risk for acute myocardial infarction (AMI) and ischemic stroke within and after 10 years of delivery, according to a study published online Jan. 26 in the...
Source: Drugs.com - Pharma News - February 3, 2023 Category: Pharmaceuticals Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
